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Human T-lymphotropic virus type-1 (HTLV-1) is the etio-
logic agent of Adult T-cell leukemia/lymphoma (ATLL),
an aggressive CD4+/CD25+T cell malignancy. The early
molecular events induced by HTLV-1 infection as well as
the role of various viral genes in the induction of leukemia
remain unclear, predominantly due to the lack of an ani-
mal model that recapitulates ATLL development. We have
previously demonstrated that HTLV-1 is capable of infect-
ing human hematopoietic progenitor and stem cells
(CD34+HP/HSCs) and that infection of CD34+HPCs has
dramatically different biological effects in comparison to
infection of mature T lymphocytes. To determine if HTLV-
1 infection of CD34+HP/HSCs recapitulates leukemogen-
esis in vivo, human hematopoiesis was reconstituted in
NOD/SCID mice by injection of human CD34+HPCs
infected  ex vivo with HTLV-1. Humanized NOD/SCID
(HU-SCID) mice infected with HTLV-1 (HTLV-1-HU-
SCID) consistently developed CD4+CD25+T cell lympho-
mas with clinical characteristics associated with ATLL at
~10 weeks post-reconstitution and show significantly ele-
vated levels of HTLV-1 infected human CD4+T cells in the
thymus, mesenteric lymph node, spleen and peripheral
blood. Lymphoma cells successfully engrafted in naïve
NOD/SCID mice when injected into the peritoneal cavity
and maintain the expression of viral proteins, gp46env and
p19gag. Moreover these infected mice showed hyperprolif-
eration of infected human stem cells (CD34+CD38-) in
the bone marrow suggesting that HP/HSCs represents
viral reservoir target cells which maintain HTLV-1 infec-
tion for extended periods of time in vivo. We speculate that
HTLV-1 infection of hematopoietic stem cells establishes
a virally-infected ''cancer stem cell'' which subsequently
gives rise ATL in patients. Notably, CD34+HPCs isolated
from HTLV-1 infected patient PBL demonstrate proviral
integrations, suggesting that these cells harbor infection in
humans. CD34+HPCs transduced with a lentivirus vector
expressing the HTLV-1 Tax gene (Tax1) also results in
CD4+/CD25+T cell leukemia/lymphoma in HU-SCID
mice, suggesting that Tax1 expression is sufficient for lym-
phomagenesis. HTLV-1 infection of humanized NOD/
SCID mice represents a novel in vivo model which recapit-
ulates viral lymphomagenesis and provides a compelling
system to investigate and characterize molecular events in
human stem cells in the initiation and progression to
ATLL.
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